Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19484458 | 1.00 | ACACB (0.37) | ACACBMAPK1L3MBTL1MAPTMEN1 | |
| SCHEMBL19484457 | 0.81 | KDM4E (0.42) | ACACBMAPTGABRA5SIGMAR1ALDH1A1 | |
| SCHEMBL19484456 | 0.81 | KDM4E (0.42) | ACACBMAPTGABRA5SIGMAR1ALDH1A1 | |
| SCHEMBL2608835 | 0.80 | GABRA5 (0.42) | MAPK1L3MBTL1MEN1KMT2AGABRA5 | |
| SCHEMBL19479367 | 0.78 | HPGD (0.47) | ACACBMAPK1L3MBTL1MAPTKMT2A | |
| SCHEMBL19484455 | 0.78 | HPGD (0.47) | ACACBMAPK1L3MBTL1MAPTKMT2A | |
| SCHEMBL20911728 | 0.77 | MEN1 (0.44) | ACACBMEN1KMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL19484272 | 0.76 | ACACB (0.40) | ACACBL3MBTL1ALDH1A1 | |
| SCHEMBL19484271 | 0.76 | ACACB (0.40) | ACACBL3MBTL1ALDH1A1 | |
| SCHEMBL2006083 | 0.74 | MAPT (0.52) | MAPTGABRA5ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442965-B1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2021-05-26 | — | — | EP | disclosed |
| US-10787432-B2 | N-[(pyridyloxy)propanyl]benzamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-09-29 | — | — | US | disclosed |
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| EP-3442958-B1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2020-05-06 | — | — | EP | disclosed |
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20190112291-A1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| WO-2017178344-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017178340-A1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | HCRTR2, HCRTR1, CNR2 | ACACB 1393/4885MAPK1 2842/4885L3MBTL1 4821/4885 |
| US-10787432-B2 | N-[(pyridyloxy)propanyl]benzamides | HCRTR1, HCRTR2, CNR1 | ACACB 2623/4885MAPK1 2683/4885L3MBTL1 4503/4885 |
| US-20190112291-A1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | HCRTR1, HCRTR2, CNR1 | ACACB 2929/4885MAPK1 2198/4885L3MBTL1 4609/4885 |
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | HCRTR2, HCRTR1, CNR1 | ACACB 2072/4885MAPK1 2536/4885L3MBTL1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.